Consensus statement of the Russian association of gerontologists and geriatricians «Novel coronavirus SARS-COV-2 infection in older adults: specific issues of prevention, diagnostics and management» (key points)

Novel coronavirus SARS-CoV-2 infection (COVID-19) is a dangerous disease for older adults. Preventive measures in this population should involve three groups of measures: 1) prevention of infection; 2) prevention of functional decline and geriatric syndromes, including social support; 3) control of chronic comorbidity. Older adults are common to present with atypical COVID-19 symptoms, and mildness of symptoms (no fever, cough, shortness of breath) does not correspond to the severity of the prognosis. Delirium may be the first manifestation of COVID-19, that is why it is screening should be widely implied. Risk of malnutrition resulting in sarcopenia increases during the hospitalization, especially if mechanical ventilation required, and promotes frailty progression and decreases quality of life after the discharge from the hospital. Geriatric assessment is an important component of the decision making process in the management of older adults. Full version was published as Tkacheva O.N., Kotovskaya Yu.V., Aleksanyan L.A., Milto A.S., Naumov A.V., Strazhesko I.D., Vorobyeva N.M., Dudinskaya E.N., Malaya I.P., Krylov K.Yu., Tyukhmenev E.A., Rozanov A.V., Ostapenko V.S., Manevich T.M., Shchedrina A.Yu., Semenov F.A., Mkhitaryan E.A., Khovasova N.O., Yeruslanova E.A., Kotovskaya N.V., Sharashkina N.V. Novel coronavirus infection SARS-CoV-2 in elderly and senile patients: prevention, diagnosis and treatment. Expert Position Paper of the Russian Association of Gerontology and Geriatrics. Cardiovascular Therapy and Prevention. 2020; 19(3): 2601. DOI: 10.15829/1728-8800-2020-2601

1. Remuzzi A., Remuzzi G. COVID-19 and Italy: what next? Lancet. 2020; 395: 1225–8. DOI: 10.1016/S0140-6736(20)30627-9

2. Porcheddu R., Serra C., Kelvin D., et al. Similarity in Case Fatality Rates (CFR) of COVID-19/SARSCOV-2 in Italy and China. J Infect Dev Ctries. 2020; 14(2): 125–8. DOI: 10.3855/jidc.12600

3. Liu K., Chen Y., Lin R., Han K. Clinical feature of COVID-19 in elderly patients: a comparison with young and middle-aged patients. J Infect. 2020; pii: S0163-4453(20)30116-X. DOI: 10.1016/j.jinf.2020.03.005

4. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К. и др. Клинические рекомендации «Старческая астения». Часть 2. Рос. журн. гериатрической медицины. 2020;2:115-3 [Tkacheva O.N., Kotovskaya Y.V., Runikhina N.K., et al. Clinical guidelines frailty. Part 2. Russian Journal of Geriatric Medicine. 2020; (2): 115–130 (In Russ.)]. DOI: 10.37586/2686-8636-2-2020-115-130

5. Gomes F., Schuetz P., Bounoure L., et al. ESPEN guideline on nutritional support for polymorbid internal medicine patients. Clin Nutr. 2018; 37: 336–53. DOI: 10.1016/j.clnu.2017.06.025

6. Volkert D., Beck A.M., Cederholm T., et al ESPEN guideline on clinical nutrition and hydration in geriatrics. Clin Nutr. 2019; 38: 10–47. DOI: 10.1016/j.clnu.2018.05.024

7. Barazzoni R., Bischoff S.C., Krznaric Z., et al, endorsed by the ESPEN Council, Espen expert statements and practical guidance for nutritional management of individuals with SARS-CoV-2 infection. Clin Nutr. 2020; 39: 1631–8. DOI: 10.1016/J.CLNU.2020.03.022

8. Ткачева О.Н., Котовская Ю.В., Рунихина Н.К. и др. Клинические рекомендации «Старческая астения». Рос. журн. гериатрической медицины. 2020; 1: 11–46 [Tkacheva O.N., Kotovskaya Y.V., Runikhina N.K., et al. Clinical guidelines on frailty. Russian Journal of Geriatric Medicine. 2020; 1: 11–46 (In Russ.)]. DOI: 10.37586/2686-8636-1-2020-11-46

9. Наумов А.В., Ткачева О.Н. Что может претендовать на роль базисной терапии хронической боли у коморбидных больных? Мед. совет. 2018; 6: 120–6 [Naumov A.V., Tkacheva O.N. What can apply for the role of basic therapy for chronic pain in comorbid patients? Meditsinskiy sovet — Medical Council. 2018; 6: 120–6 (In Russ.)]. DOI: 10.21518/2079-701X-2018-6-120-126

10. Grant W.B., Lahore H., McDonnell S.L., et al. Evidence That Vitamin D Supplementation Could Reduce Risk of Influenza and COVID-19. Nutrients. 2020 Apr 2; 12(4): E988. DOI: 10.3390/nu12040988

11. Poudel-Tandukar K., Poudel K.C., et al. Serum 25-hydroxyvitamin d levels and C-reactive protein in persons with human immunodeficiency virus infection. AIDS Res Hum Retrovir. 2013; 29: 528–34. DOI: 10.1089/AID.2012.0120

12. Zhang M., Gao Y., Tian L., et al. Association of serum 25-hydroxyvitamin D3 with adipokines and inflammatory marker in persons with prediabetes mellitus. Clin Chim Acta. 2017; 468: 152–8. DOI: 10.1016/j.cca.2017.02.022

13. Dancer R.C., Parekh D., Lax S., et al. Vitamin D deficiency contributes directly to the acute respiratory distress syndrome (ARDS). Thorax. 2015; 70: 617–24. DOI: 10.1136/thoraxjnl-2014-206680

14. Thickett D.R., Moromizato T., Litonjua A.A., et al. Association between prehospital vitamin D status and incident acute respiratory failure in critically ill patients: A retrospective cohort study. BMJ Open Respir Res. 2015;2:e000074. DOI: 10.1136/bmjresp-2014-000074

15. Wimalawansa S.J. Global epidemic of coronavirus–COVID-19: What we can do to minimze risks. Eur J Biomed Pharm Sci. 2020; 7: 432–8

16. Driggin E., Madhavan M.V., Bikdeli B., et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Coll Card. 2020; 75(18): 2352–71. DOI: 10.1016/j.jacc.2020.03.031

17. Rossi G.P., Sanga V., Barton M.E., et al. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients. Hum Biol Med. 2020 Apr 6; 9: e57278. DOI: 10.7554/eLife.57278

18. Danser A.H.J., Epstein M., Batlle D. ReninAngiotensin System Blockers and the COVID-19 Pandemic. At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020; 75: 1382–5. DOI: 10.1161/HYPERTENSIONAHA.120.15082

19. HFSA/ACC/AHA Statement Addresses Concerns Re: Using RAAS Antagonists in COVID-19. ttps://www.acc.org/latest-in-cardiology/articles/2020/03/17/08/59/hfsa-acc-aha-statement-addresses-concerns-re-using-raas-antagonists-in-COVID-1

20. Арутюнов Г.П., Козиолова Н.А., Тарловская Е.И. и др. Согласованная позиция экспертов Евразийской ассоциации терапевтов по некоторым новым механизмам патогенеза COVID-19: фокус на гемостаз, вопросы гемотрансфузии и систему транспорта газов крови. Кардиология. 2020; 60(5): 9–19 [Arutyunov G.P., Koziolova N.A., Tarlovskaya E.I., et al. The Agreed Experts’ Position of the Eurasian Association of Therapists on Some new Mechanisms of COVID-19 Pathways: Focus on Hemostasis, Hemotransfusion Issues and Blood gas Exchange. Kardiologiia. 2020; 60(5): 9–19 (In Russ.)]. DOI: 10.18087/cardio.2020.5.n1132

21. Gupta R., Ghosh A., Singh A.K., Misra F. Clinical Considerations for Patients With Diabetes in Times of COVID-19 Epidemic. Diabetes Metab Syndr. 2020;1 4(3): 211–2. DOI: 10.1016/j.dsx.2020.03.002

22. Zhao Q., Meng M., Kumar R., et al. The Impact of COPD and Smoking History on the Severity of Covid-19: A Systemic Review and MetaAnalysis. J Med Virol. 2020 Apr 15. DOI: 10.1002/jmv.25889

23. Tal-Singer R., Crapo J.D. COPD at the time of COVID-19: a COPD Foundation perspective. Chronic Obstr Pulm Dis. 2020; 7(2): 73–5. DOI: http://doi.org/10.15326/jcopdf.7.2.2020.0149

24. https://www.ema.europa.eu/en/news/emagives-advice-use-non-steroidal-anti-inflammatoriescovid-19

25. Hunt R., Lazebnik L.B., Marakhouski Y.C., et al. International Consensus on Guiding Recommendations for Management of Patients with Nonsteroidal Anti-inflammatory Drugs Induced Gastropathy-ICON-G. Euroasian J Hepatogastroenterol. 2018; 8(2): 148–60

26. Ткачева О.Н., Остроумова О.Д., Котовская Ю.В. и др. Депрескрайбинг ингибиторов протонной помпы у пациентов пожилого и старческого возраста. Клин. фармакология и терапия. 2019; 28(1): 70–4 [Tkacheva O.N., Ostroumova O.D., Kotovskaya Yu.V., et al. Deprescribing of proton pump inhibitors in the elderly. Clinical Pharmacology and Therapy. 2019; 28(1): 70–4 (In Russ.)]. DOI: 10.32756/0869-5490-2019-1-70-74

27. Zhang S., Qing Q., Bai Y., et al. Rebamipide helps defend against nonsteroidal anti-inflammatory drugs induced gastroenteropathy: a systematic review and meta-analysis. Dig Dis Sci. 2013 Jul; 58(7): 1991–2000. DOI: 10.1007/s10620-013-2606-0

28. Tajima K., Hattori T., Takahashi H., et al. Rebamipide suppresses TNF-α production and macrophage infiltration in the conjunctiva. Vet Ophthalmol. 2018 Jul; 21(4): 347–52. DOI: 10.1111/vop.12510

29. Fukuda K., Ishida W., Tanaka H., et al. Inhibition by rebamipide of cytokine-induced or lipopolysaccharide-induced chemokine synthesis in human corneal fibroblasts. Br J Ophthalmol.2014 Dec; 98(12): 1751–5. DOI: 10.1136/bjophthalmol-2014-305425

30. Fu R., Jiang Y., Zhou J., Zhang J. Rebamipide ophthalmic solution modulates the ratio of T helper cell 17/regulatory T cells in dry eye disease mice. Mol Med Rep. 2019 May; 19(5): 4011–8. DOI: 10.3892/mmr.2019.10068

31. Lee S.Y., Kang E.J., Hur G.Y., et al. The inhibitory effects of rebamipide on cigarette smokeinduced airway mucin production. Respir Med. 2006; 100(3): 503–11. doi: 10.1016/j.rmed.2005.06.006

32. Nikolich-Zugich J., Knox K.S., Rios C.T., et al. SARS-CoV-2 and COVID-19 in older adults: what we may expect regarding pathogenesis, immune responses, and outcomes. Version 2. Geroscience. 2020 Apr; 42(2): 505–14. DOI: 10.1007/s11357-020-00186-0

33. Shahid Z., Kalayanamitra R., McClafferty B., et al. COVID-19 and Older Adults: What We Know. J Am Geriatr Soc. 2020 May; 68(5): 926–9. DOI: 10.1111/jgs.16472

34. Atypical Covid-19 presentations in older people — the need for continued vigilance. https://www.bgs.org.uk/blog/atypical-covid-19-presentations-inolder-people-the-need-for-continued-vigilance

35. Kotfis K., Williams Roberson S., Wilson J.E., et al. COVID-19: ICU delirium management during SARS-CoV-2 pandemic. Version 2. Crit Care. 2020 Apr 28; 24(1): 176. DOI: 10.1186/s13054-020-02882-x

36. Norman D.C. Fever in the elderly. Clin Infect Dis. 2000; 31(1): 148–51. DOI: 10.1086/313896

37. Coronavirus: Managing delirium in confirmed and suspected cases. https://www.bgs.org.uk/resources/coronavirus-managing-delirium-inconfirmed-and-suspected-cases

38. Singer P., Blaser A.R., Berger M.M., et al. ESPEN guideline on clinical nutrition in the intensive care unit. Clin Nutr. 2019; 38: 48–79. DOI: 10.1016/j.clnu.2018.08.037

39. Bikdeli B., Madhavan M.V., Jimenez D., et al. COVID-19 and Thrombotic or Thromboembolic Disease: Implications for Prevention, Antithrombotic Therapy, and Follow-up. JACC. 2020. DOI: 10.1016/j.jacc.2020.04.031

40. Thachil J., Tang N., Gando S., et al. ISTH interim guidance on recognition and management of coagulopathy in COVID‐19. J Thromb Haemost. 2020. DOI: 10.1111/jth.14810

41. Dolhnikoff M., Duarte-Neto A.N., Monteiro R.A.A., et al. Pathological evidence of pulmonary thrombotic phenomena in severe COVID-19. J Thromb Haemost. 2020. DOI: 10.1111/JTH.14844

42. Carsana L., Sonzogni A., Nasr A. Pulmonary post-mortem findings in a large series of COVID-19 cases from Northern Italy. DOI: 10.1101/2020.04.19.20054262

43. Helms J., Tacquard C., Severac F., et al. High risk of thrombosis in patients with severe SARSCoV-2 infection: a multicenter prospective cohort study. Intensive Care Med. 2020. DOI: 10.1007/s00134-020-06062-x

44. Klok F., Kruip M., van der Meer N., et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. 2020; 191: 145–7. DOI: 10.1016/j.thromres.2020.04.013

45. Menter T., Haslbauer J., Nienhold R., et al. Post-mortem examination of COVID19 patients reveals diffuse alveolar damage with severe capillary congestion and variegated findings of lungs and other organs suggesting vascular dysfunction. Histopathology. 2020. DOI: 10.1111/his.14134

46. Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020; 18: 844–7.

47. Llitjos J., Leclerc M., Chochois C., et al. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. 2020 April. DOI: 10.1111/jth.14869

48. Koyama N., Sasabe H., Miyamoto G. Involvement of Cytochrome P450 in the Metabolism of Rebamipide by the Human Liver. Xenobiotica. 2002 Jul; 32(7): 573–86. DOI: 10.1080/00498250210130591

49. Kompanje E.J.O., Piers R.D., Benoit D.D. Causes and consequences of disproportionate care in intensive care medicine. Curr Opin Crit Care. 2013; 19: 630–5. DOI: 10.1097/MCC.0000000000000026

50. EuGMS Task Force on COVID-19. Topic 4. Ethical principles concerning proportionality of critical care during the 2020 COVID-19 pandemic in Belgium: advice by the Belgian Society of Intensive care medicine. https://www.eugms.org

51. COVID-19 rapid guideline: critical care in adults. https://www.nice.org.uk/guidance/ng159

52. Kunz R., Minder M. COVID-19 pandemic: palliative care for elderly and frail patients at home and in residential and nursing homes. Swiss Med Wkly. 2020 Mar 24; 150: w20235. DOI: 10.4414/smw.2020.20235

53. Аналитический бюллетень НИУ ВШЭ об экономических и социальных последствиях коронавируса в России и в мире от 14 мая 2020 г. [HSE analytical Bulletin: Economic and social consequences of coronavirus in Russia and in the world. 14 May 2020] https://www.hse.ru/mirror/pubs/share/364606313.pdf

54. http://www.euro.who.int/en/media-centre/sections/statements/2020/statement-invest-in-theoverlookedand-unsung-build-sustainable-peoplecentred-long-term-care-in-the-wake-of-covid-19